Advance Online
Advance Online

ETICOVO Approved for PsA and Psoriasis

FDA approves biosimilar to ENBREL.

A man and a woman share headphones at a restaurant.

The U.S. Food and Drug Administration approved biosimilar ETICOVO (enanercept-ykro) for the treatment of plaque psoriasis and psoriatic arthritis. It is a biosimilar to ENBREL, a biologic that first became available in 1998. [1]

Taken by injection, ETICOVO is a tumor necrosis factor blocker. It is manufactured by Samsung Bioepis Co., Ltd. [1]

Biosimilars

Get the facts on what biosimilars are, how they can be used for treatment, and what you should know about them.

Learn more

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2025 National Psoriasis Foundation/USA


The National Psoriasis Foundation is a qualified 501(c)(3) EIN 93-0571472.


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.